title: Medical malpractice implications of PSA testing for early detection of prostate cancer.
abstract: Prostate cancer screening is controversial. We conducted a national survey of primary care physicians and urologists to examine their use of prostate-specific antigen testing and their views on medical liability issues involved.
authors.affiliation: Harvard Medical School, Boston, USA.
authors.forename: M M
authors.initials: MM
authors.lastname: Collins
authors.forename: F J
authors.initials: FJ
authors.lastname: Fowler
authors.forename: R G
authors.initials: RG
authors.lastname: Roberts
authors.forename: J E
authors.initials: JE
authors.lastname: Oesterling
authors.forename: G J
authors.initials: GJ
authors.lastname: Annas
authors.forename: M J
authors.initials: MJ
authors.lastname: Barry
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D005260:Female; D006801:Humans; D008297:Male; D008318:Malpractice / Q000706:statistics & numerical data; D008404:Massachusetts; D008875:Middle Aged; D010818:Practice Patterns, Physicians'; D017430:Prostate-Specific Antigen / Q000097:blood*; D011470:Prostatic Hyperplasia / Q000175:diagnosis; D011471:Prostatic Neoplasms / Q000517:prevention & control*
chemical_list: D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen